23-Hydroxybetulinic acid (Synonyms: 23-羟基白桦酸; Anemosapogenin)

目录号: HY-N0566 纯度: 99.01%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

23-hydroxybetulinic acid是具有抗癌活性的生物化合物。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

23-Hydroxybetulinic acid Chemical Structure

CAS No. : 85999-40-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥380	In-stock
5 mg	￥1000	In-stock
10 mg	￥1700	In-stock
25 mg	￥3100	In-stock
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of 23-Hydroxybetulinic acid:

23-Hydroxybetulinic acid (Standard) 询价

23-Hydroxybetulinic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

23-hydroxybetulinic acid is one of the bioactive components responsible for its anticancer activity. In vitro: 23-hydroxybetulinic acid also shows different proliferation inhibitory activity against B16, HeLa, and HUVEC, with the IC50 value of 78.5, 80, and 94.8 uM, respectively. 23-hydroxybetulinic acid can promote cell cycle arrest at S phase and induce apoptosis via intrinsic pathway. 23-hydroxybetulinic acid disrupts mitochondrial membrane potential significantly (p<0.01) and selectively downregulates the levels of Bcl-2, survivin and upregulates Bax, cytochrome C, cleaved caspase-9 23-hydroxybetulinic acid can induce apoptosis in K562 cells. [1] 23-hydroxybetulinic acid enhances sensitivity of doxorubicin (DOX, ADR) on MCF-7/ADR cell lines, indicating its potential to be developed as a novel MDR modulator.[2] 23-HBA significantly improve the sensitivity of the tumor to doxorubicin. [3]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A2780	IC₅₀	79.12 μM Compound: 1; HBA	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
A-375	IC₅₀	41.99 μM Compound: 1	Antiproliferative activity against human A375 cells after 72 hrs by MTT assay Antiproliferative activity against human A375 cells after 72 hrs by MTT assay	[PMID: 21496972]
A-375	IC₅₀	76.3 μM Compound: 1; HBA	Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
A549	IC₅₀	51.44 μM Compound: 23-HBA; 4	Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35803175]
A549	IC₅₀	87.6 μM Compound: HBA	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17275295]
B16	IC₅₀	18.68 μM Compound: 1	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 21496972]
B16	IC₅₀	29.87 μM Compound: 1, HBA	Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
B16	IC₅₀	29.87 μM Compound: 1, HBA	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 25529742]
B16	IC₅₀	29.87 μM Compound: HBA	Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay	[PMID: 25247772]
B16	IC₅₀	83.04 μM Compound: HBA	Cytotoxicity against mouse B16 cells by MTT assay Cytotoxicity against mouse B16 cells by MTT assay	[PMID: 17275295]
B16-F10	IC₅₀	24.46 μM Compound: 1; 23-HBA	Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 30344912]
Bel-7402	IC₅₀	39.67 μM Compound: 1, HBA	Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
Bel-7402	IC₅₀	39.67 μM Compound: 1, HBA	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 25529742]
Bel-7402	IC₅₀	39.67 μM Compound: HBA	Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay	[PMID: 25247772]
Bel-7402	IC₅₀	97.32 μM Compound: HBA	Cytotoxicity against human BEL-7402 cells by MTT assay Cytotoxicity against human BEL-7402 cells by MTT assay	[PMID: 17275295]
C6	IC₅₀	99.48 μM Compound: HBA	Cytotoxicity against mouse C6 cells by MTT assay Cytotoxicity against mouse C6 cells by MTT assay	[PMID: 17275295]
HeLa	IC₅₀	46.22 μM Compound: 1	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21496972]
HeLa	IC₅₀	52.39 μM Compound: 1, HBA	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
HeLa	IC₅₀	52.39 μM Compound: 1, HBA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25529742]
HeLa	IC₅₀	52.39 μM Compound: HBA	Antiproliferative activity against human HeLa cells after 72 hrs MTT assay Antiproliferative activity against human HeLa cells after 72 hrs MTT assay	[PMID: 25247772]
HepG2	IC₅₀	41.41 μM Compound: 1	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21496972]
HepG2	IC₅₀	71.84 μM Compound: 1; HBA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
HFL1	IC₅₀	75 μM Compound: 23-HBA; 4	Cytotoxicity against human HFL1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HFL1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35803175]
HL-60	IC₅₀	45.15 μM Compound: 1, HBA	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
HL-60	IC₅₀	45.15 μM Compound: 1, HBA	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 25529742]
HL-60	IC₅₀	45.15 μM Compound: HBA	Antiproliferative activity against human HL60 cells after 72 hrs MTT assay Antiproliferative activity against human HL60 cells after 72 hrs MTT assay	[PMID: 25247772]
HT-29	IC₅₀	54.81 μM Compound: 23-HBA; 4	Antiproliferative activity against human HT-29 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35803175]
L02	IC₅₀	79.15 μM Compound: 1; HBA	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
M14	IC₅₀	50 μM Compound: 7	Cytotoxicity against human M14 cells after 48 hrs by MTT assay Cytotoxicity against human M14 cells after 48 hrs by MTT assay	[PMID: 21954959]
MCF7	IC₅₀	20.83 μM Compound: 1; 23-HBA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30344912]
MCF7	IC₅₀	46.61 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 21496972]
MCF7	IC₅₀	74.98 μM Compound: 1; HBA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
NCI-H596	IC₅₀	58.12 μM Compound: 23-HBA; 4	Antiproliferative activity against NQO1-deficient human NCI-H596 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against NQO1-deficient human NCI-H596 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35803175]

分子量

472.70

Formula

C₃₀H₄₈O₄

CAS 号

85999-40-2

性状

固体

颜色

White to off-white

中文名称

23-羟基白桦酸；23-羟基白桦脂酸

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (211.55 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1155 mL	10.5775 mL	21.1551 mL
5 mM	0.4231 mL	2.1155 mL	4.2310 mL
10 mM	0.2116 mL	1.0578 mL	2.1155 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.29 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.01%

选择批次：

Data Sheet (617 KB) SDS (252 KB)

COA (294 KB) HNMR (203 KB) CNMR (180 KB) RP-HPLC (589 KB) MS (184 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Liu M et al. Cytotoxicity of the compounds isolated from Pulsatilla chinensis saponins and apoptosis induced by 23-hydroxybetulinic acid. Pharm Biol. 2015 Jan;53(1):1-9. [Content Brief]

[2]. Zhang DM et al. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol Pharm. 2012 Nov 5;9(11):3147-59. [Content Brief]

[3]. Zheng Y et al. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo. J Ethnopharmacol. 2010 Apr 21;128(3):615-22. [Content Brief]

23-Hydroxybetulinic acid 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1155 mL	10.5775 mL	21.1551 mL	52.8877 mL
	5 mM	0.4231 mL	2.1155 mL	4.2310 mL	10.5775 mL
	10 mM	0.2116 mL	1.0578 mL	2.1155 mL	5.2888 mL
	15 mM	0.1410 mL	0.7052 mL	1.4103 mL	3.5258 mL
	20 mM	0.1058 mL	0.5289 mL	1.0578 mL	2.6444 mL
	25 mM	0.0846 mL	0.4231 mL	0.8462 mL	2.1155 mL
	30 mM	0.0705 mL	0.3526 mL	0.7052 mL	1.7629 mL
	40 mM	0.0529 mL	0.2644 mL	0.5289 mL	1.3222 mL
	50 mM	0.0423 mL	0.2116 mL	0.4231 mL	1.0578 mL
	60 mM	0.0353 mL	0.1763 mL	0.3526 mL	0.8815 mL
	80 mM	0.0264 mL	0.1322 mL	0.2644 mL	0.6611 mL
	100 mM	0.0212 mL	0.1058 mL	0.2116 mL	0.5289 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

23-Hydroxybetulinic acid85999-40-2Anemosapogenin23-羟基白桦酸23-羟基白桦脂酸ApoptosisInhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

23-Hydroxybetulinic acid (Synonyms: 23-羟基白桦酸; Anemosapogenin)

Customer Review

Other Forms of 23-Hydroxybetulinic acid:

23-Hydroxybetulinic acid 相关抗体

23-Hydroxybetulinic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

23-Hydroxybetulinic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z